News

MSCA Presidency Conference "Researchers' careers: multiple pathways" 18 and 19 April 2024: web stream available

Published on
| 2 years ago
Programmes
  • MSCA
  • MSCA

In case you were not able to register for onsite attendance in Mons at the Marie Skłodowska-Curie Actions (MSCA) Presidency Conference 2024 on the multiple pathways of researchers' careers rest assured that you can participate anyway. Did you know that it is possible to watch the conference from anywhere in the world on your screen?

The whole conference except the parallel sessions on 18 April (workshop 1, 2 & 3 and roundtable 2) are web streamed live. Check out the biographies of all speakers at the conference and the 15 MSCA Falling Walls Lab contestants. The full agenda and web stream of the conference are available on the MSCA Presidency Conference website here.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2049 articles available Browse all news
  • EIC

EIC Work Programme 2027 adopted

The 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...

Read more
  • Defence
  • DIRS

Start2Def 2026 call open

The Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.